epithalon vs dsip

updated October 25, 2026

epithalon (tier C) vs dsip (tier C): what each is, why each got its grade, half-life and source counts side by side.

epithalon · tier C

russian longevity peptide. one lab. one cohort. the lifespan claims have never been replicated.

tier rationale

C-tier because the biology is plausible but the marketing has badly outrun the evidence. A real peptide from a real research program, with some mechanistic basis in pineal signaling and melatonin modulation. But the commercial sales pitch, telomerase activation and human lifespan extension, is the overreach. Single-lab data, single-cohort clinical trial, no Western replication. Community reports a sleep benefit that's probably real, but that's a much smaller claim than what vendors sell the compound on. Moves to B-tier only if independent replication of the telomerase or lifespan claims appears.

dsip · tier C

isolated 1977 as a sleep peptide. 50 years of trials, no clinical breakthrough. community uses it anyway.

tier rationale

C-tier because DSIP has had nearly 50 years of on-again off-again clinical research without producing convergent evidence of efficacy. Some positive trials exist, particularly for sleep and alcohol withdrawal, but the field never reached consensus and the compound never achieved drug-approval status anywhere. The mechanism is unclear: no confirmed receptor, no clean pathway. Not D-tier because the trial literature is real and includes legitimate positive findings, the peptide is well-characterized biochemically, and community responders do seem to exist. Not B-tier because the gap between 'occasionally shown to help' and 'consistently shown to help' is exactly what separates C from B.

at a glance

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.